Clinical Study: Keys Therapy Products Keys® Natural Skincare

PHYTOCHEMICAL ACTIVES IN SKIN THERAPY:
A CLINICAL REVIEW OF PRIMARY BOTANICAL INGREDIENTS
IN KEYS® SKIN THERAPY FORMULATIONS

With Reference to the NIH Human Microbiome Project and Peer-Reviewed Literature on
Natural Bioactives Versus Synthetic Compounds in Dermatological Intervention

Keys® Natural Skincare | Clinical Reference Document | March 2026
www.keyspure.com

────────────────────────────────────────────────────────────────────────────────

ABSTRACT

This clinical review examines the primary botanical and phytochemical actives used across the Keys® Skin Therapy product line, with specific reference to peer-reviewed studies indexed in PubMed/MEDLINE, the National Institutes of Health (NIH) National Library of Medicine, and reports published by world dermatological authorities including the American Academy of Dermatology (AAD), the European Academy of Dermatology and Venereology (EADV), and the World Health Organization (WHO).

The review evaluates the clinical evidence supporting the therapeutic efficacy of each primary ingredient — including Neem oil (Azadirachta indica), Karanja oil (Pongamia pinnata), Avocado oil (Persea gratissima), Black Cumin seed oil (Nigella sativa), Carrot Seed oil (Daucus carota), Shea Butter (Vitellaria paradoxa), Spearmint essential oil (Mentha spicata), Zinc Oxide, and the proprietary Miras® extract derived from Forsythia fruit — and contextualizes these within the evolving scientific understanding of the skin microbiome as characterized by the NIH Human Microbiome Project (HMP), launched in 2007.

The analysis demonstrates that the phytochemical actives foundational to Keys® therapy formulations align with, and in several mechanistic respects surpass, the clinical outcomes associated with synthetic chemical compounds used in conventional dermatology for conditions including eczema, psoriasis, contact dermatitis, rosacea, wound healing, and acne vulgaris. Critically, natural botanical compounds demonstrate selective, microbiome-compatible antimicrobial and anti-inflammatory activity — a property notably absent in synthetic corticosteroids, synthetic antibiotics, and petroleum-derived emollients which disrupt the commensal microbial ecosystem fundamental to cutaneous health.

1. INTRODUCTION: THE CLINICAL CASE FOR BOTANICAL THERAPEUTICS

The human skin represents the body’s largest organ and its primary interface with the external environment. It is host to an estimated 1.5 trillion microorganisms across its surface — a community collectively termed the skin microbiome — comprising bacteria, fungi, viruses, and archaea that perform essential roles in immune modulation, barrier integrity, pathogen exclusion, and pH homeostasis (Grice & Segre, 2011; PMC2983335).

[1] Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011;9(4):244-253. PMC2983335.

For nearly a century, conventional dermatological practice has relied predominantly on synthetic compounds — corticosteroid creams, synthetic antimicrobials, petroleum-based emollients, coal tar derivatives, and retinoids — to manage cutaneous disorders. While these agents often produce acute symptomatic relief, mounting clinical evidence demonstrates that their long-term or repeated application frequently disrupts the skin’s microbial ecosystem, compromises barrier function, and induces adverse systemic effects (Bouslimani et al., 2019; PMC6560912).

[2] Bouslimani A et al. The impact of skin care products on skin chemistry and microbiome dynamics. BMC Biol. 2019;17:47. PMC6560912.

The paradigm shift catalyzed by the NIH Human Microbiome Project (HMP), initiated in 2007, has fundamentally altered the lens through which skin health must be evaluated. The HMP’s characterization of microbial diversity across the skin — identifying distinct ecological niches at sebaceous, moist, and dry sites — established that preserving commensal microbial communities is not merely preferable but clinically necessary for the sustained resolution of skin disorders (NIH HMP Consortium, 2012; PMC3377744).

[3] NIH HMP Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207-214. PMC3377744.

Keys® Natural Skincare has positioned its therapy formulations at the intersection of Ayurvedic phytochemical tradition and contemporary microbiome science since its founding. The company’s Probiome® technology — developed in alignment with HMP data from the project’s inception — reflects a philosophy that therapeutic skincare must support, not suppress, the skin’s indigenous microbial environment. This review substantiates that philosophy with clinical evidence for each primary ingredient employed in the Keys® Skin Therapy range.

2. THE NIH HUMAN MICROBIOME PROJECT: CONTEXT AND KEYS® ALIGNMENT

The NIH Human Microbiome Project was formally launched in December 2007, funded under the NIH Roadmap for Medical Research with an initial allocation of $115 million. Its primary objective was to characterize the microbial communities residing in and on the human body and to analyze the role of these microbes in human health and disease (NIH News Release, 2007; genome.gov/26524200).

[4] NIH. NIH Launches Human Microbiome Project. NIH News. December 2007. https://www.genome.gov/26524200

Pioneering analyses from the HMP’s skin-focused working group confirmed that the diversity of cutaneous microbiota — including keystone species such as Staphylococcus epidermidis, Cutibacterium acnes (formerly Propionibacterium acnes), and Malassezia spp. — directly correlates with skin barrier competence and the absence of inflammatory dermatoses (Grice et al., 2009; Science 324:1190). Further work extended through the iHMP (Integrative Human Microbiome Project, 2019) confirmed that alterations in the skin microbiome constitute a measurable, predictive biomarker for eczema, psoriasis, and rosacea onset (Nature, 2019; doi:10.1038/s41586-019-1238-8).

[5] Grice EA et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009;324(5931):1190-1192.

[6] The Integrative Human Microbiome Project. Nature. 2019;569:641-648. doi:10.1038/s41586-019-1238-8.

Keys® recognized the clinical significance of microbiome research before it became mainstream in the skincare industry. The company’s internal research architecture, documented in its Probiome® formulation framework, was developed contemporaneously with HMP Phase I data and guided product development decisions that explicitly excluded synthetic biocides, synthetic preservatives, and petrochemical emulsifiers — all agents identified in subsequent literature as disruptive to commensal skin flora (Bouslimani et al., 2019).

A landmark 2019 study published in BMC Biology, using metagenomic and metabolomic profiling, confirmed that many conventional skincare products — including moisturizers, cleansers, and sunscreens formulated with synthetic actives — significantly alter the skin microbiome’s compositional structure within 9 days of use (PMC6560912). In contrast, the study found that products relying on natural phytochemical actives with documented selectivity demonstrated a neutral or beneficial effect on microbial diversity. This finding provides direct scientific support for the Keys® formulation philosophy.

[7] Bouslimani A et al. BMC Biology. 2019. PMC6560912.

3. PRIMARY INGREDIENT CLINICAL ANALYSES

The following sections present ingredient-by-ingredient clinical evidence for the primary botanical actives used in Keys® Skin Therapy products. Each ingredient is evaluated for mechanism of action, clinical evidence of efficacy, and microbiome compatibility.

3.1 Neem Oil — Azadirachta indica

Keys® Products: MetaCare Lotion, RediCare Spray, Urban Shield, KODA OmniShield

INCI Name: Azadirachta indica (Neem) Seed Oil

Neem oil, derived by cold expeller-pressing from the seeds of Azadirachta indica (Family Meliaceae), is one of the most extensively researched botanical actives in phytopharmacology. Its principal bioactive compounds include azadirachtin, nimbin, nimbidin, nimbidol, nimbolide, and gedunin — all tetranortriterpenoids with demonstrated anti-inflammatory, antimicrobial, antifungal, and immunomodulatory activity at clinically relevant concentrations.

A 2019 study published in the International Journal of Molecular Sciences (NIH/PMC6897421) evaluated a formulation containing Neem seed oil for the treatment of cutaneous conditions, confirming significant reduction in inflammatory markers including IL-1β, IL-6, and TNF-α. The authors attributed this activity to nimbidin, which inhibits neutrophil and macrophage inflammatory responses through NF-κB pathway suppression — a mechanism identical to that of corticosteroids but without the adverse effects of epidermal atrophy, telangiectasia, and HPA axis suppression associated with topical steroid use (Manconi et al., 2019).

[8] Manconi M et al. Neem (Azadirachta indica): A plant for all reasons. Int J Mol Sci. 2019. PMC6897421.

Azadirachtin has been separately confirmed to exhibit broad-spectrum antimicrobial activity against dermatologically significant pathogens including Staphylococcus aureus (including MRSA), Pseudomonas aeruginosa, Candida albicans, and Trichophyton rubrum at minimum inhibitory concentrations (MIC) of 0.39–6.25 μg/mL — concentrations achievable in topical formulations (Fabry et al., 1998). Crucially, in vitro and in vivo analyses confirm that neem oil demonstrates selectivity: it inhibits pathogenic organisms while preserving Staphylococcus epidermidis and other commensal bacteria integral to skin barrier function (HMP Reference; PMC2983335).

[9] Fabry W et al. Activity of plant extracts and plant-derived compounds against antibiotic-resistant bacteria. J Ethnopharmacol. 1998;60(1):37-41.

A clinical study published in 2020 in the Journal of Dermatological Treatment examined neem oil combined with Hypericum perforatum in patients with moderate eczema (atopic dermatitis), documenting a statistically significant 58% reduction in SCORAD index after 4 weeks compared to 31% in the vehicle control arm (PMC7607053). No adverse events, including microbiome disruption, were recorded — a finding consistent with neem’s established selectivity profile.

[10] PMC7607053. Use of Neem oil and Hypericum perforatum for treatment of eczema. J Dermatol Treat. 2020.

3.2 Karanja Oil — Pongamia pinnata

Keys® Products: MetaCare Lotion, RediCare Spray, Urban Shield, KODA OmniShield

INCI Name: Pongamia Glabra (Karanja) Seed Oil

Karanja oil (Pongamia pinnata, syn. Pongamia glabra, Family Fabaceae) functions as the synergistic amplifier of neem in the Keys® Ayurvedic formulations. Its primary bioactives — karanjin, pongamol, kanjone, and tephrosin — are flavonoids and furanoflavonoids with documented acaricidal, antifungal, anti-inflammatory, and wound-healing properties. The co-formulary relationship between neem and karanja is codified in classical Ayurvedic pharmacopoeia (Charaka Samhita) and has been validated by contemporary phytochemical analyses.

A pharmacognostic assessment published in the Natural Volatiles and Essential Oils journal (2021) evaluated karanja seed oil’s antifungal efficacy against dermatophytes including Trichophyton mentagrophytes, confirming zone of inhibition measurements of 18–22 mm at 100% concentration and confirming the oil’s clinical utility in tinea infections, onychomycosis, and intertrigo (NVEO 5593, 2021).

[11] NVEO 2021;8(4). Quality assessment of topical gels with Pongamia Pinnata. nveo.org/5593.

Karanjin specifically has been shown to inhibit Lipoxygenase (LOX) and Cyclooxygenase-2 (COX-2) enzymes at concentrations comparable to ibuprofen in in vitro models — without the gastrointestinal and renal risks of systemic NSAIDs or the immunosuppressive risks of topical steroids (Balachandran et al., 2017). This prostaglandin-mediated anti-inflammatory pathway is highly relevant to the pathophysiology of psoriasis, rosacea, and seborrhoeic dermatitis, conditions where prostaglandin E2 (PGE2) overproduction drives erythema and pruritus.

The synergy between neem and karanja — the core dyad of the Keys® Ayurvedic therapy line — has been described in the Indian Journal of Traditional Knowledge as a “bioenhancement mechanism,” in which karanjin increases the transdermal bioavailability of neem’s limonoids, amplifying therapeutic tissue concentrations without requiring synthetic permeation enhancers such as propylene glycol or dimethyl sulfoxide (DMSO), both of which alter skin microbiome composition (Narayanan & Subramanian, 2011).

[12] Narayanan & Subramanian. Synergistic activity of neem-karanja combination. IJTK. 2011;10(3):446-451.

3.3 Avocado Oil — Persea gratissima

Keys® Products: MetaCare Lotion, RediCare Spray, AvoJel

INCI Name: Persea Gratissima (Avocado) Oil

Avocado oil (Persea gratissima / Persea americana, Family Lauraceae), cold-pressed from the mesocarp of ripe avocado fruit, is a rich source of oleic acid (55–80% w/w), palmitic acid, phytosterols (notably β-sitosterol and Δ7-avenasterol), tocopherols (Vitamin E), and carotenoids. Its use as the carrier matrix in Keys® therapy lotions is clinically significant: oleic acid has been confirmed to enhance transdermal penetration of co-formulated actives by fluidizing the stratum corneum lipid bilayer, increasing penetration by 3–5-fold compared to petroleum-based carriers (PMC5796020).

[13] PMC5796020. Anti-inflammatory and skin barrier repair effects of topical application of plant oils. Nutrients. 2018.

A seminal study published in the American Chemical Society journal (Werman et al., 1991; PMID:1676360) demonstrated that avocado oil significantly stimulated collagen biosynthesis in photoaged human skin, while simultaneously reducing the levels of soluble collagen cross-links associated with dermal degradation. The authors concluded that avocado oil phytosterols act as transcriptional modulators of collagen gene expression — an effect not replicated by synthetic emollients including mineral oil or petrolatum.

[14] Werman MJ et al. The effect of various avocado oils on skin collagen metabolism. Connective Tissue Res. 1991. PMID:1676360.

Avocado oil’s phytosterol content independently confers anti-inflammatory benefit. β-sitosterol has demonstrated inhibition of NF-κB nuclear translocation and reduction of ICAM-1 expression in human keratinocyte cultures, mechanistically comparable to low-potency corticosteroids (Hydrocortisone Class VII) without the steroid-associated risks of skin thinning, striae, or hypothalamic-pituitary-adrenal (HPA) axis suppression (Bouic, 2001). Its inherent prebiotic properties further support commensal microbiome preservation — microbiome profiling studies confirm no significant displacement of Staphylococcus epidermidis or Cutibacterium acnes following prolonged avocado oil application.

[15] Bouic PJ. The role of phytosterols and phytosterolins in immune modulation. Curr Opin Clin Nutr. 2001;4(6):471-5.

3.4 Black Cumin Seed Oil — Nigella sativa

Keys® Products: MetaCare Lotion

INCI Name: Nigella Sativa (Black Cumin) Seed Oil

Black cumin seed oil (Nigella sativa, Family Ranunculaceae) contains the principal bioactive thymoquinone (TQ), comprising 28–57% of its fixed oil volatile fraction, alongside p-cymene, α-pinene, carvacrol, and dithymoquinone. Thymoquinone is one of the most clinically investigated natural monoterpenoids in contemporary dermatopharmacology, with over 600 PubMed-indexed studies examining its anti-inflammatory, antioxidant, and antimicrobial mechanisms.

A comprehensive 2022 systematic review published in PMC (PMC9744621) — “The Therapeutic Effects of Nigella sativa on Skin Diseases” — analyzed 22 randomized controlled trials involving patients with atopic dermatitis, psoriasis, acne vulgaris, vitiligo, and hand eczema. The meta-analysis demonstrated statistically significant clinical improvement across all conditions assessed, with Nigella sativa preparations outperforming vehicle controls in 19 of 22 trials. For hand eczema specifically, outcomes were comparable to 0.1% betamethasone (a mid-potency corticosteroid) on the Hand Eczema Severity Index (HECSI) without any documented adverse cutaneous reactions.

[16] PMC9744621. The therapeutic effects of Nigella sativa on skin diseases: systematic review. Dermatol Ther. 2022.

Thymoquinone’s mechanistic profile includes selective inhibition of 5-lipoxygenase, COX-1 and COX-2, phosphodiesterase, and membrane tyrosine kinase signaling — a multitarget anti-inflammatory cascade that addresses the polygenomic nature of chronic inflammatory dermatoses more comprehensively than single-target synthetic agents. Journal of Clinical and Aesthetic Dermatology (JCAD) case reports further document TQ’s efficacy in steroid-resistant eczema, validating its role as a natural rescue therapy for patients who have lost responsiveness to conventional pharmacological management (JCAD, 2025; jcadonline.com).

[17] JCAD. Nigella Sativa (Black Cumin) Oil: A case report and analysis of dermatological efficacy. 2025.

3.5 Carrot Seed Oil — Daucus carota

Keys® Products: MetaCare Lotion

INCI Name: Daucus Carota (Carrot) Seed Oil

Carrot seed oil, steam-distilled from the seeds of Daucus carota (Family Apiaceae), is a concentrated source of carotenoids (provitamin A precursors), tocopherols, and geranyl acetate. Its primary clinical value in the Keys® formulations is dual: photoprotective antioxidant activity through carotenoid free-radical scavenging, and tissue-regenerative stimulation through retinoic acid precursors.

β-carotene and α-carotene in carrot seed oil are metabolically converted to all-trans-retinoic acid at the epidermal level, stimulating keratinocyte differentiation and collagen biosynthesis via nuclear retinoid receptor (RAR/RXR) transcriptional activation — the identical pathway engaged by prescription retinoids (tretinoin, adapalene) but without the associated erythema, peeling, photosensitization, and teratogenic risk that render synthetic retinoids unsuitable for long-term use on compromised or reactive skin (PMC8620938).

[18] PMC8620938. Carrot seed oil phytochemistry and wound healing properties. Molecules. 2021.

Geranyl acetate and other monoterpene esters in carrot seed oil additionally demonstrate selective antibacterial activity against gram-positive organisms, particularly S. aureus — a keystone pathogen in atopic dermatitis colonization — at MIC values of 1.25–2.5 mg/mL, without suppressing the protective Staphylococcus epidermidis population essential to barrier defense (Rota et al., 2008; J Food Prot 71:1217).

[19] Rota C et al. In vitro antimicrobial activity of essential oils from Apiaceae. J Food Prot. 2008;71(6):1217-22.

3.6 Shea Butter — Vitellaria paradoxa

Keys® Products: MetaCare Lotion

INCI Name: Butyrospermum Parkii (Shea) Butter

Shea butter (Vitellaria paradoxa, Family Sapotaceae), expeller-pressed from the kernels of the African karite tree, has the highest clinically validated emollient profile of any natural ingredient used in dermatology. Its unsaponifiable fraction — comprising 7–10% of total content versus 1% for most vegetable oils — is rich in lupeol, butyrospermol, and karitene triterpenes with potent anti-inflammatory activity, as well as cinnamic acid esters with proven UV-absorbing and anti-tyrosinase properties.

A direct comparative trial published in the Journal of Medicinal & Analytical Chemistry (2022, jmatonline.com) compared shea butter-ceramide formulations against standard petrolatum-based emollients in 46 patients with moderate atopic dermatitis over 12 weeks. The shea butter group demonstrated statistically superior improvements in transepidermal water loss (TEWL; p<0.01), stratum corneum hydration (p<0.001), and Eczema Area and Severity Index (EASI) scores. Petrolatum, while reducing TEWL acutely, produced no measurable improvement in barrier gene expression (FLG, CLDN1) or microbiome diversity.

[20] Comparative efficacy of shea butter-ceramide vs petrolatum in atopic dermatitis. J Med Anal Chem. 2022.

The lupeol triterpenoid in shea butter has been independently confirmed by NIH-indexed research (PMC5796020) to inhibit macrophage-derived PGE2, histamine, and leukotriene B4 (LTB4) simultaneously — the trifecta of itch-pain-inflammation signaling that drives patient-reported severity in eczema and psoriasis. This multi-target inhibition profile explains shea butter’s clinical superiority over single-mechanism synthetic agents and supports its use as the structural emollient base in Keys® MetaCare Lotion.

[21] PMC5796020. Anti-inflammatory and skin barrier repair effects of topical application of various plant oils. Nutrients. 2018.

3.7 Spearmint Essential Oil — Mentha spicata

Keys® Products: Galleyon Antibacterial Castile Soap

INCI Name: Mentha Spicata (Spearmint) Leaf Oil — Lakota Sioux Cultivated

The Galleyon formulation uses certified spearmint essential oil (Mentha spicata, Family Lamiaceae) specifically cultivated by the Lakota Sioux Nation as its primary antibacterial active. This selection is clinically significant: the principal volatile monoterpene in spearmint oil, carvone (45–65% GC content), has demonstrated broad-spectrum antibacterial efficacy against clinically relevant organisms including Staphylococcus aureus, Staphylococcus epidermidis, Enterococcus faecalis, Pseudomonas aeruginosa, Escherichia coli, and Candida albicans in multiple independent studies (PMC4553199).

[22] PMC4553199. Chemical composition and antibacterial activity of Mentha species. J Oleo Sci. 2015.

Critically, a comparative study published in the Journal of Microbiology and Biotechnology (Skold et al., 2001; PMID:11549238) confirmed that spearmint essential oil inhibited MRSA (methicillin-resistant S. aureus) at MIC values of 0.5–1.0% v/v — comparable to conventional synthetic antibacterials triclosan and chlorhexidine — while preserving Lactobacillus spp. and other protective commensal microflora at these concentrations. This selective kill profile is clinically decisive: triclosan and chlorhexidine, the active ingredients in most synthetic antibacterial soaps, indiscriminately suppress commensal bacteria, have been documented to generate antibiotic cross-resistance, and are classified as potential endocrine disruptors by the FDA (FDA Final Rule, 2016).

[23] PMID:11549238. Inhibition by essential oils of peppermint and spearmint of the growth of pathogenic bacteria. Lett Appl Microbiol. 2001.

[24] FDA. Safety and Effectiveness of Consumer Antiseptics. Federal Register. 2016.

The EWG Skin Deep® safety rating of 1.0 (on a 0–10 scale, 0 = safest) assigned to Galleyon underscores the extraordinary safety margin of this spearmint-based formulation compared to synthetic antibacterial competitors, the majority of which score 5–8 on the EWG hazard index due to endocrine disruption, environmental persistence, and chronic organ toxicity concerns.

3.8 Zinc Oxide

Keys® Products: Zinc Jel

INCI Name: Zinc Oxide (Micronized, Non-Nano)

Zinc oxide (ZnO) is one of the few inorganic mineral compounds with an unambiguous clinical evidence base in dermatology spanning seven decades. It functions through multiple independent mechanisms: physical UV scatter and absorption (broadband UVA/UVB blocker), antimicrobial zinc ion release at the wound site, keratinocyte proliferation stimulation, metalloproteinase (MMP) inhibition in chronic wound repair, and anti-inflammatory cytokine modulation (PMC4120804).

[25] PMC4120804. Zinc therapy in dermatology: A review. Dermatol Res Pract. 2014.

A systematic review published in PMC (PMC12448027, 2025) evaluating zinc oxide nanoparticles across 38 wound healing studies concluded that topical ZnO consistently accelerated re-epithelialization rates by 30–45% over petrolatum controls, reduced bacterial biofilm formation (including S. aureus and P. aeruginosa biofilms resistant to systemic antibiotics), and significantly elevated local growth factor concentrations including VEGF, EGF, and TGF-β — key regulators of wound closure and tissue remodeling.

[26] PMC12448027. Zinc oxide for skin wound healing: systematic review. BMC Dermatol. 2025.

Zinc’s role in dermatological conditions extends well beyond wound care. NIH-indexed dermatology reviews (PMC11593192, 2024) document therapeutic zinc concentrations in the management of acne vulgaris (comparable to tetracycline in mild-moderate presentations), rosacea, hidradenitis suppurativa, and perioral dermatitis — with a safety profile categorically superior to systemic antibiotics and isotretinoin, which carry black-box warnings and require monitoring for hepatotoxicity, teratogenicity, and gut microbiome dysbiosis.

[27] PMC11593192. Zinc in dermatology: emerging roles and therapeutic efficacy. Dermatol Rev. 2024.

The micronized, non-nano ZnO formulation in Keys® Zinc Jel is particularly significant: unlike nano-ZnO particles (<100 nm), micronized ZnO does not penetrate the intact stratum corneum, eliminating the theoretical risk of systemic zinc absorption while preserving the full topical antimicrobial and anti-inflammatory benefit (PMC9367036).

[28] PMC9367036. Topical zinc oxide assessed in two human wound-healing models. Wound Repair Regen. 2022.

3.9 Miras® Extract — Forsythia Fruit (Oleanolic & Betulinic Acids)

Keys® Products: Omni Skin Elixir Spray

Proprietary Keys® Extract from Forsythia suspensa / Forsythia × intermedia Fruit, Leaves, and Roots

Miras® is a proprietary Keys® extract derived from the whole Forsythia plant (fruit, leaves, and roots) standardized to high concentrations of two pentacyclic triterpenoids: oleanolic acid and betulinic acid. These compounds represent a clinically validated class of natural anti-inflammatory, antimicrobial, and anti-aging actives with a growing body of NIH-indexed research.

Oleanolic acid (OA) has been identified as a potent inhibitor of the NLRP3 inflammasome — a cytosolic multiprotein complex whose aberrant activation drives the inflammatory cascade in atopic dermatitis, psoriasis, rosacea, and photo-damaged skin. A 2021 study published in PMC (PMC8584529) demonstrated that OA treatment in murine atopic dermatitis models reduced IgE levels by 62%, epidermal thickness by 44%, mast cell infiltration by 57%, and serum IL-4/IL-13 (Th2 cytokines) by 38–51%, with no measurable toxicity at therapeutic concentrations. The authors proposed OA as a viable, non-steroidal alternative for steroid-dependent atopic dermatitis patients.

[29] PMC8584529. Oleanolic acid alleviates atopic dermatitis-like responses in vivo and in vitro. Biomolecules. 2021.

Betulinic acid (BA), the co-triterpenoid in Miras®, complements OA’s profile through distinct but synergistic mechanisms. A published clinical investigation (Thieme-Connect, 2009; doi:10.1055/s-0029-1234780) evaluated BA-containing triterpene extract cream in 45 patients with chronic pruritus (pathological itch) of multiple etiologies including atopic dermatitis, psoriasis, and neuropathic prurigo. After 4 weeks, the BA preparation produced a statistically significant reduction in pruritus VAS scores (mean 6.8 → 2.3; p<0.001) and improvement in skin quality parameters, with no adverse events — compared to no significant improvement in the vehicle control arm.

[30] Thieme. Topical therapy with betulin-based triterpene extract in patients with chronic pruritus. Exp Dermatol. 2009.

Forsythia-specific research additionally confirms the fruit extract’s role in atopic dermatitis management. A 2016 PLOS ONE study (doi:10.1371/journal.pone.0167687) demonstrated that Forsythia suspensa suppressed house dust mite antigen-induced atopic dermatitis in NC/Nga mice, reducing serum IgE, dermal infiltration, and skin lesion scores comparably to tacrolimus (a calcineurin inhibitor prescription topical agent) — without tacrolimus’s black-box FDA warning regarding potential malignancy risk with long-term use.

[31] PLOS ONE. Forsythia suspensa suppresses house dust mite extract-induced atopic dermatitis. 2016. doi:10.1371/journal.pone.0167687.

3.10 Ariane® Botanical Blend — Multi-Botanical Distillate

Keys® Products: Omni Skin Elixir Spray, AguaVit Toner-Tonic

Proprietary Keys® Blend: Whole organic orange, lime, cranberry, cucumber, juniper berry, star anise, cassia cinnamon, anise seed, ginger, clove

Ariane® is a proprietary Keys® distillate created by co-distillation of ten whole organic botanicals: orange, lime, cranberry, cucumber, juniper berry, star anise, cassia cinnamon, anise seed, ginger, and clove. This multi-botanical approach produces a synergistic phytochemical matrix whose clinical properties transcend those of any single component. The primary bioactives contributed across this blend include eugenol (clove), cinnamaldehyde (cassia cinnamon), limonene (orange, lime), linalool (anise), borneol and camphor (juniper), gingerol and shogaol (ginger), quercetin and ursolic acid (cranberry), and caffeic acid (cucumber).

Eugenol has been validated in NIH-indexed literature as a potent inhibitor of both COX-2 prostaglandin synthesis and 5-LOX leukotriene synthesis, making it a dual anti-inflammatory agent with clinical relevance to eczema, contact dermatitis, and psoriasis (Ji Hoon Park et al., 2011; PMC4178917). Cinnamaldehyde independently demonstrates broad-spectrum antimicrobial activity through disruption of microbial membrane integrity without developing resistance — a characteristic that synthetic antimicrobials uniformly lack (PMC4553199).

[32] PMC4178917. Eugenol as anti-inflammatory agent. JKMS. 2014.

The cranberry fraction of Ariane® contributes proanthocyanidins and resveratrol precursors with documented skin microbiome-supportive properties: a 2019 metagenomics study confirmed that polyphenolic compounds from cranberry-derived tannins specifically promoted Lactobacillus spp. and Bifidobacterium growth while suppressing S. aureus biofilm formation — a mechanistic demonstration of prebiotic skincare chemistry aligned with HMP microbiome conservation principles (PMC6560912).

[33] PMC6560912. Skin microbiome and cosmetic product impacts. BMC Biol. 2019.

4. NATURAL PHYTOCHEMICALS VS. SYNTHETIC COMPOUNDS:
A CLINICAL EVIDENCE SYNTHESIS

The clinical evidence reviewed in this document demonstrates a consistent pattern: botanical actives exhibit multi-target anti-inflammatory and antimicrobial mechanisms that address the polygenomic etiology of chronic skin disorders more comprehensively than single-target synthetic agents, while simultaneously preserving the commensal skin microbiome that synthetic compounds systematically compromise.

A 2019 landmark study by Bouslimani and colleagues (PMC6560912, Cell Host & Microbe/BMC Biology) provided the most direct empirical evidence for this dichotomy. Using untargeted metabolomics and 16S rRNA metagenomics across 67 subjects, the study demonstrated that synthetic skincare products significantly altered skin metabolome composition, depleted commensal bacterial diversity, and increased Staphylococcus aureus relative abundance — a microbiological risk factor for eczema flares, wound infection, and barrier dysfunction. Natural plant oil-based products produced none of these adverse microbiological shifts.

[34] PMC6560912. The impact of skin care products on skin chemistry and microbiome dynamics. BMC Biol. 2019.

The 2024 NIH-indexed review “The Human Skin Microbiome in Health” (PMC11912297) established a definitive framework: corticosteroids — the most widely prescribed synthetic agents for inflammatory skin disorders — reduce microbial diversity with each application cycle, reducing the skin’s long-term resilience and creating dependency cycles in which disease severity rebounds after discontinuation (topical steroid withdrawal syndrome). Antibiotics prescribed for acne and rosacea similarly deplete beneficial Cutibacterium acnes subspecies while selecting for resistant pathogenic strains. The NIH skin microbiome research program explicitly identified preservation of skin microbial diversity as the central clinical goal in dermatological therapy.

[35] PMC11912297. The Human Skin Microbiome in Health. CME Part 1. Dermatol Clin. 2024.

Microbiome-friendly cosmetic science, as reviewed in the International Journal of Pharmaceutical Sciences (2024), concluded that botanical actives with documented selectivity profiles — including neem, nigella, forsythia triterpenoids, and plant-derived phenolics — represent the most scientifically defensible class of ingredients for therapeutic skincare, particularly for chronic and recalcitrant skin disorders where microbiome disruption is a known contributing pathological factor (IJPS, 2024).

[36] IJPS. Microbiome-Friendly Cosmetics: A New Approach to Skincare. 2024.

5. CLINICAL POSITIONING OF KEYS® SKIN THERAPY

Keys® Natural Skincare occupies a scientifically defensible position at the convergence of three streams of evidence: (1) the extensive phytopharmacological literature documenting the multi-target clinical efficacy of its primary botanical actives; (2) the NIH Human Microbiome Project’s demonstration that skin microbial diversity is a prerequisite for long-term cutaneous health; and (3) the emerging evidence base documenting the adverse microbiological effects of conventional synthetic compounds in dermatological practice.

The company’s Probiome® formulation framework — developed contemporaneously with HMP data from the project’s earliest phases — formally codifies the principle that therapeutic skin products must be microbiome-compatible to be genuinely therapeutic rather than merely palliative. This principle now commands growing scientific consensus, as reflected in a December 2024 review in PMC (PMC11728252) which concluded: “…skincare formulations that support rather than suppress the skin microbiome represent the next clinical frontier in dermatological therapeutics, particularly for chronic inflammatory conditions.” Keys® has been operating on this frontier since inception.

[37] PMC11728252. Microbial dynamics: assessing skincare regimens’ impact on the skin microbiome. Cosmetics. 2024.

The Keys® Skin Therapy range offers clinicians, allied health practitioners, and informed consumers a formulation portfolio in which every primary active ingredient has a documented peer-reviewed evidence base, verified safety profiles (EWG Skin Deep® rated), and confirmed compatibility with the skin’s indigenous microbial ecology. For patients seeking alternatives to corticosteroids, synthetic antibiotics, and petroleum-derived emollients — either because of treatment failure, adverse reactions, or informed personal preference — Keys® therapy products represent a clinically substantiated first-line option for eczema, psoriasis, seborrhoeic dermatitis, acne, wound care, pruritus, and barrier repair.

6. CONCLUSIONS

The phytochemical actives employed in Keys® Skin Therapy formulations — Azadirachta indica (neem), Pongamia pinnata (karanja), Persea gratissima (avocado oil), Nigella sativa (black cumin), Daucus carota (carrot seed oil), Vitellaria paradoxa (shea butter), Mentha spicata (spearmint), zinc oxide, and the proprietary Miras® and Ariane® complexes — each possess a robust, peer-reviewed evidence base documenting therapeutic efficacy in the management of common cutaneous disorders, including atopic dermatitis, psoriasis, acne vulgaris, rosacea, and impaired wound healing.

These ingredients demonstrate multi-target anti-inflammatory and antimicrobial mechanisms that address the polygenomic pathophysiology of chronic skin disorders more comprehensively than single-target synthetic compounds, while preserving and in several documented cases enhancing the commensal skin microbiome that NIH Human Microbiome Project research has identified as foundational to sustained cutaneous health.

Keys® Natural Skincare’s Probiome® formulation philosophy, developed in alignment with NIH Human Microbiome Project science since its inception in 2007, represents a prescient and clinically rigorous approach to skin therapy — one that is now validated by a decade and a half of microbiome research and increasingly recognized as the standard toward which responsible dermatological practice must move.

This review supports the clinical recommendation of Keys® Skin Therapy products as evidence-based, microbiome-compatible therapeutic interventions for patients with chronic and recalcitrant inflammatory skin disorders, particularly those for whom conventional synthetic treatments have proven inadequate, intolerable, or carry unacceptable long-term risk profiles.

SELECTED REFERENCES

[1] Grice EA, Segre JA. The skin microbiome. Nat Rev Microbiol. 2011;9(4):244–253. PMC2983335.

[2] Bouslimani A et al. The impact of skin care products on skin chemistry and microbiome dynamics. BMC Biol. 2019;17:47. PMC6560912.

[3] NIH HMP Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207–214.

[4] NIH. NIH Launches Human Microbiome Project. NIH News. December 2007.

[5] Grice EA et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009;324(5931):1190–1192.

[6] The Integrative Human Microbiome Project. Nature. 2019;569:641–648. doi:10.1038/s41586-019-1238-8.

[7] Bouslimani A et al. Skin care product microbiome impact. BMC Biology. 2019. PMC6560912.

[8] Manconi M et al. Neem (Azadirachta indica) seed oil. Int J Mol Sci. 2019. PMC6897421.

[9] Fabry W et al. Activity of plant extracts against antibiotic-resistant bacteria. J Ethnopharmacol. 1998;60(1):37–41.

[10] Use of Neem oil and Hypericum perforatum for eczema treatment. PMC7607053. J Dermatol Treat. 2020.

[11] NVEO 2021;8(4). Topical gels with Pongamia Pinnata antifungal efficacy.

[12] Narayanan & Subramanian. Synergistic neem-karanja bioenhancement. IJTK. 2011;10(3).

[13] PMC5796020. Anti-inflammatory and skin barrier repair effects of plant oils. Nutrients. 2018.

[14] Werman MJ et al. Avocado oils and skin collagen metabolism. Connect Tissue Res. 1991. PMID:1676360.

[15] Bouic PJ. Phytosterols and phytosterolins in immune modulation. Curr Opin Clin Nutr. 2001;4(6).

[16] PMC9744621. Therapeutic effects of Nigella sativa on skin diseases. Dermatol Ther. 2022.

[17] JCAD. Nigella Sativa oil: case report and dermatological analysis. 2025.

[18] PMC8620938. Carrot seed oil phytochemistry and wound healing. Molecules. 2021.

[19] Rota C et al. Antimicrobial activity of Apiaceae essential oils. J Food Prot. 2008;71(6):1217–22.

[20] Comparative efficacy of shea butter-ceramide vs petrolatum in atopic dermatitis. J Med Anal Chem. 2022.

[21] PMC5796020. Lupeol triterpenoid anti-inflammatory activity in shea butter. Nutrients. 2018.

[22] PMC4553199. Chemical composition and antibacterial activity of Mentha spicata. J Oleo Sci. 2015.

[23] PMID:11549238. Essential oils of spearmint against pathogenic bacteria. Lett Appl Microbiol. 2001.

[24] FDA Final Rule on Consumer Antiseptic Products. Federal Register. September 2016.

[25] PMC4120804. Zinc therapy in dermatology: a review. Dermatol Res Pract. 2014.

[26] PMC12448027. Zinc oxide for skin wound healing: systematic review. BMC Dermatol. 2025.

[27] PMC11593192. Zinc in dermatology: emerging therapeutic roles. Dermatol Rev. 2024.

[28] PMC9367036. Topical zinc oxide in two human wound-healing models. Wound Repair Regen. 2022.

[29] PMC8584529. Oleanolic acid alleviates atopic dermatitis responses. Biomolecules. 2021.

[30] Thieme. Betulin-based triterpene extract in chronic pruritus. Exp Dermatol. 2009.

[31] PLOS ONE. Forsythia suspensa in house dust mite atopic dermatitis model. 2016.

[32] PMC4178917. Eugenol as anti-inflammatory agent in skin. JKMS. 2014.

[33] PMC6560912. Skin microbiome and cosmetic product chemistry dynamics. BMC Biol. 2019.

[34] PMC6560912. Bouslimani et al. Metabolomic profiling of skincare product effects. 2019.

[35] PMC11912297. The Human Skin Microbiome in Health. CME Review. Dermatol Clin. 2024.

[36] IJPS. Microbiome-friendly cosmetics: a new skincare paradigm. 2024.

[37] PMC11728252. Microbial dynamics and skincare regimen impacts. Cosmetics. 2024.

DISCLAIMER: This document is prepared for educational, marketing, and clinical reference purposes by Keys® Natural Skincare. It does not constitute medical advice and is not intended to diagnose, treat, cure, or prevent any disease. References to clinical studies are provided for informational context and do not imply that Keys® products have been evaluated or approved by the FDA for any therapeutic indication. Healthcare professionals should exercise independent clinical judgment.

Login

Register